Characterization and improvement of anti-cancer properties of second generation antagonists of Mdm2 oncoprotein
2016/21/D/NZ7/00596
Keywords
Descriptors
- NZ7_14: Farmacja, farmakoterapia, farmakologia
- NZ1_1: Biologia molekularna
- NZ3_3: Apoptoza
Panel
NZ7 – Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution
Uniwersytet Jagielloński, Wydział Chemii
Voivodeship: małopolskie
Principal investigator (from the host institution)
Number of co-investigators in the project: 4
Call
SONATA 11 – announced on 2016-03-15
- Amount awarded
- 688 320 PLN
- Project start date
- 2017-02-06
- Project end date
- 2020-02-05
- Project duration
- 36 months (the same as in the proposal)
- Project status
- Project settled
Project description
Download the project description in a pdf file
Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Equipment purchased [PL]
- Komora laminarna II klasy bezpieczeństwa mikrobiologicznego. Cost: 17 958 PLN
- Komora laminarna II klasy bezpieczeństwa mikrobiologicznego.
- Zestaw zwiększający możliwości mikroskopu fluorescencyjnego. Cost: 95 000 PLN
Information in the final report
Publication in academic press/journals (8)
-
A therapeutic patent overview of MDM2/X-Targeted Therapies (2014-2018)
- Authors:
- Skalniak L, Surmial E, Holak TA
- Academic press:
- Expert Opinion On Therapeutic Patents (year: 2019, volume: 46082, pages: 46042), Publisher: TAYLOR & FRANCIS LTD, 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
- Status:
- Published
- DOI:
- 10.1080/13543776.2019.1582645 – link to the publication
-
Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists
- Authors:
- Kocik J, Machula M, Wisniewska A, Surmiak E, Holak TA, Skalniak L
- Academic press:
- Cancers (Basel) (year: 2019, volume: 11(7), pages: pii: E1014), Publisher: MDPI, ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
- Status:
- Published
- DOI:
- 10.3390/cancers11071014 – link to the publication
-
Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
- Authors:
- Skalniak L, Kocik J, Polak J, Skalniak A, Rak M, Wolnicka-Glubisz A, Holak TA
- Academic press:
- Cancers (year: 2018, volume: 10, pages: 11), Publisher: MDPI, ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
- Status:
- Published
- DOI:
- 10.3390/cancers10110396 – link to the publication
-
Fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53wt osteosarcoma cells
- Authors:
- Skalniak L, Twarda-Clapa A, Neochoritis CG, Surmiak E, Machula M, Wisniewska A, Labuzek B, Ali AM, Krzanik S, Dubin G, Groves M, Dömling A, Holak TA
- Academic press:
- FEBS Journal (year: 2019, volume: 286(7), pages: 1360-1374), Publisher: WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
- Status:
- Published
- DOI:
- 10.1111/febs.14774 – link to the publication
-
1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers
- Authors:
- Twarda-Clapa A, Krzanik S, Kubica K, Guzik K, Labuzek B, Neochoritis CG, Khoury K, Kowalska K, Czub M, Dubin G, Dömling A, Skalniak L, Holak TA
- Academic press:
- Journal of Medicinal Chemistry (year: 2017, volume: 60, pages: 4234-4244), Publisher: AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
- Status:
- Published
- DOI:
- 10.1021/acs.jmedchem.7b00104 – link to the publication
-
Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction
- Authors:
- Neochoritis CG, Atmaj J, Twarda-Clapa A, Surmiak E, Skalniak L, Köhler LM, Muszak D, Kurpiewska K, Kalinowska-Tłuścik J, Beck B, Holak TA, Dömling A
- Academic press:
- European Journal of Medicinal Chemistry (year: 2019, volume: 182, pages: 111588), Publisher: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
- Status:
- Published
- DOI:
- 10.1016/j.ejmech.2019.111588 – link to the publication
-
Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions
- Authors:
- Ricardo MG, Ali AM, Plewka J, Surmiak E, Labuzek B, Neochoritis CG, Atmaj J, Skalniak L, Zhang R, Holak TA, Groves M, Rivera DG, Dömling A
- Academic press:
- ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (year: 2020, volume: 59(13), pages: 5235-5241), Publisher: WILEY-V C H VERLAG GMBH, POSTFACH 101161, 69451 WEINHEIM, GERMANY
- Status:
- Published
- DOI:
- 10.1002/anie.201916257 – link to the publication
-
Bioactive Macrocyclic Inhibitors of the PD‐1/PD‐L1 Immune Checkpoint
- Authors:
- Magiera-Mularz K, Skalniak L, Zak KM, Musielak B, Rudzinska-Szostak E, Berlicki L, Kocik J, Grudnik P, Sala D, Zarganes‐Tzitzikas T, Shaabani S, Domling A, Dubin G, Holak TA
- Academic press:
- Angewandte Chemie International Edition (year: 2017, volume: 56, pages: 13732-13735), Publisher: WILEY-V C H VERLAG GMBH, POSTFACH 101161, 69451 WEINHEIM, GERMANY
- Status:
- Published
- DOI:
- 10.1002/anie.201707707 – link to the publication
Articles in post-conference publications (1)
-
Insufficient cancer cell elimination by p53-inducer Idasanutlin (R) (RG7388) leads to the generation of secondary drug-resistance
- Authors:
- Skalniak L, Kocik J, Rak M, Holak TA
- Conference:
- The 43'rd FEBS Congress (year: 2018, pages: 343-343), Publisher: WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
- Date:
- conference 7-12 lipca 2018
- Status:
- Published